Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cerebral deposition of the beta-amyloid peptide (A beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A beta (ref. 1) and the subsequent cloning of its precursor protein, no direct evidence for the actual production of discrete A beta has been reported. Here we investigate whether A beta is present in human biological fluids using antibodies specific for an epitope within A beta that spans the site of normal constitutive cleavage. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A beta and a novel A beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies that shed light on the physiological role of Aβ in non-diseased brains show that Aβ plays a role in synaptic transmission and is involved in learning and memory formation [18–22].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [18]
In the citing paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [3]
In the citing paper
“The demonstration that A-related peptides with the same N terminals as the CTFs documented here are present in conditioned medium of cultured cells (Seubert et al., 1992;Naslund et al., 1994;Simons et al., 1996;Wang et al., 1996;Xu et al., 1998)”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Seubert et al., 1992
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Cited by
Items 1,301–1,400 of 1,726
Alzheimer's disease: Recent advances in molecular pathology and genetics
McLoughlin, D. M., & Lovestone, S. (1994) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930090602 · Cited by 12
Human β-secretase and Alzheimer’s disease
Citron, M. (2001) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.5.3.341 · Cited by 12
Larner, A. J. (1995) · BioEssays · doi:10.1002/bies.950170912 · Cited by 11
Maggio, J. E., Esler, W. P., Stimson, E. R., Jennings, J. M., Ghilardi, J. R., & Mantyh, P. W. (1995) · Science · doi:10.1126/science.7604268 · Cited by 11
Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain
Majou, D., & Dermenghem, A.-L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148681 · Cited by 11
A human neuron Alzheimer’s disease model reveals barriers to senolytic translatability
Walton, C. C., Wang, E. Y., Lee, S., Siebrand, C. J., Bergo, N. J., Mayeri, Z., & Andersen, J. K. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01822-7 · Cited by 10
Istıflı, E. S., & Sarıkürkçü, C. (2021) · International Journal of Plant Based Pharmaceuticals · doi:10.62313/ijpbp.2021.7 · Cited by 11
Wang, H., Kakizawa, T., Taniguchi, A., Mizuguchi, T., Kimura, T., & Kiso, Y. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.06.017 · Cited by 12
Liu, Y., Cong, L., Han, C., Li, B., & Dai, R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201127104539 · Cited by 11
Macq, A.-F., Philippe, B., & Octave, J. N. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90803-6 · Cited by 10
An Ultrasensitive Assay for Diagnosis of Alzheimer's Disease
Funke, S. A., Birkmann, E., Henke, F., Görtz, P., Lange‐Asschenfeldt, C., Riesner, D., & Willbold, D. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0670 · Cited by 10
Dorpe, J. A. V., Smeijers, L., Dewachter, I., Spittaels, K., den Haute, C. V., Tesseur, I. C., Sciot, R., & LEUVEN, F. V. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82614-7 · Cited by 11
Amyloid beta peptides, locus coeruleus-norepinephrine system and dense core vesicles
Ross, J. A., Reyes, B. A. S., & Bockstaele, E. J. V. (2018) · Brain Research · doi:10.1016/j.brainres.2018.03.009 · Cited by 13
Goswami, S., Kareem, O., Goyal, R. K., Mumtaz, S. M., Tonk, R. K., Gupta, R., & Pottoo, F. H. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666201001105553 · Cited by 11
Evaluation of neural damage in Duchenne muscular dystrophy patients.
Salam, E. A., Abdel-Meguid, I. E., Shatla, R., & Korraa, S. (2014) · PubMed Central · Cited by 15
Canine leptomeningeal organ culture: a new experimental model for cerebrovascular ß-amyloidosis
Prior, R., D’Urso, D., Frank, R. W., Prikulis, I., Wihl, G., & Pavlaković, G. (1996) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(96)00036-2 · Cited by 12
Esler, W. P., Marshall, J. R., Stimson, E. R., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (2002) · Amyloid · doi:10.3109/13506120209072439 · Cited by 11
Li, M., & Smith, C. P. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(96)00031-7 · Cited by 10
Metal Cations Defibrillize the Amyloid Beta-Protein Fibrils
Chauhan, V. P. S., Ray, I., Chauhan, A., Węgiel, J., & Wísniewski, H. M. (1997) · Neurochemical Research · doi:10.1023/a:1022079709085 · Cited by 11
van Dijk, R., Fischer, D. F., Sluijs, J. A., Sonnemans, M. A. F., Hobo, B., Mercken, L., Mann, D. M. A., Hol, E. M., & van Leeuwen, F. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02528.x · Cited by 12
“The remaining C-terminal fragment is cleaved in the transmembrane domain by c-secretase, generating Ab peptides of 40 or 42 amino acids long (Haass et al. 1992; Seubert et al. 1992).”
Stanyer, L., Betteridge, D. J., & Smith, C. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2003.11.005 · Cited by 14
Beta-amyloid oligomers: recent developments
Borutaite, V., Morkuniene, R., & Valincius, G. (2011) · bmc · doi:10.1515/bmc.2011.019 · Cited by 9
“The effect of solvents on the conformations of Amyloid b-peptide (1-42) studied by molecular dynamics simulation.”
BackgroundInfluentialEffect of Cholesterol on C99 Dimerization: Revealed by Molecular Dynamics Simulations
Li, C.-D., Junaid, M., Shan, X., Wang, Y., Wang, X., Khan, A., & Wei, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.872385 · Cited by 9
“Aβ accumulation leads to a series of pathological changes, including neuronal death and amyloid plaque, which are pathologically characterized within the gray matter of an AD patient’s brain (Seubert et al., 1992; Iwatsubo et al., 1994; Kirkitadze et al., 2002; Walsh et al., 2002).”
BackgroundKimura, N., Sasaki, K., Masuda, T., Ataka, T., Matsumoto, M., Kitamura, M., Nakamura, Y., & Matsubara, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01650-1 · Cited by 12
In vitro neurotoxicity of amyloid β-peptide cross-linked by transglutaminase
Shinagawa, R., Masuda, S., Sasaki, R., Ikura, K., & Takahata, K. (1997) · Cytotechnology · doi:10.1023/a:1007999114779 · Cited by 9
“But the finding that A is constitutively produced in the normal metabolism of amyloid precursor protein (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992) indicates that A modifications other than the noncovalent self-aggregation may also operate on the formation of the insoluble deposits.”
BackgroundMolecular probes for cellular imaging of post-translational proteoforms
Suraritdechachai, S., Lakkanasirorat, B., & Uttamapinant, C. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00190f · Cited by 11
Song, H., Ritz, S., Knoll, W., & Sinner, E. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.06.020 · Cited by 10
Platelet α- and β-secretase activities: A preliminary study in normal human subjects
Smith, C., Prichard, B. N. C., & Cooper, M. B. (2009) · Platelets · doi:10.1080/09537100802334434 · Cited by 9
Mouedden, M. E., Haseldonckx, M., Mackie, C. E., Meert, T. F., & Mercken, M. H. (2005) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2005.02.002 · Cited by 9
Analysis of nicastrin gene phylogeny and expression in zebrafish
Lim, A., Nik, S. H. M., Ebrahimie, E., & Lardelli, M. T. (2015) · Development Genes and Evolution · doi:10.1007/s00427-015-0500-9 · Cited by 10
Helix-Switch Enables C99 Dimer Transition between the Multiple Conformations
Li, C.-D., Junaid, M., Chen, H., Ali, A., & Wei, D. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00559 · Cited by 10
Particulate forms of APP in the extracellular milieu of cultured cells
Barber, K., Enam, S., Bodovitz, S., Falduto, M. T., Frail, D. E., & Klein, W. L. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90057-8 · Cited by 9
Theoretical studies on Alzheimer's disease: structures of β-amyloid aggregates
Kim, S. T., & Weaver, D. F. (2000) · Journal of Molecular Structure THEOCHEM · doi:10.1016/s0166-1280(00)00485-1 · Cited by 9
Chauhan, A., Chauhan, V. P. S., Rubenstein, R., Węgiel, J., & Wísniewski, H. M. (1997) · Neurochemical Research · doi:10.1023/a:1027379926976 · Cited by 10
The Pathophysiology of Alzheimer’s Disease
Selkoe, D. J. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_4 · Cited by 16
Self-citationRacchi, M., Johnston, J. A., Flood, F., Cowburn, R. F., & Govoni, S. M. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3380777 · Cited by 9
Tanimukai, S., Hasegawa, H., Nakai, M., Yagi, K., Hirai, M., Saito, N., Taniguchi, T., Terashima, A., Yasuda, M., Kawamata, T., et al. (2002) · Neuroreport · doi:10.1097/00001756-200203250-00037 · Cited by 9
Gardella, J. E., Gorgone, G., Candela, L., Ghiso, J. A., Castaño, E. M., Frangione, B., & Gorevic, P. D. (1993) · Biochemical Journal · doi:10.1042/bj2940667 · Cited by 9
Kametani, F., Tanaka, K., Tokuda, T., & Allsop, D. (1995) · Brain Research · doi:10.1016/0006-8993(95)01195-1 · Cited by 9
Implication of Novel Biochemical Property of β-Amyloid
Elbaum, D., Brzyska, M., Bacia, A., & Alkon, D. L. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2024 · Cited by 9
Proteolysis of Alzheimer's disease β-amyloid precursor protein by factor Xa
Haas, C., Aldudo, J., Cazorla, P., Bullido, M. J., de Miguel, C., Vázquez, J., & Valdivieso, F. (1997) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(97)00094-0 · Cited by 9
Larner, A. J., & Rossor, M. N. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.10.1115 · Cited by 10
Ledoux, S., Bergeron, C., Nalbantoglu, J. N., Gauthier, S. G., & Cashman, N. R. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11681-l · Cited by 9
Alzheimer's disease: progress in pathological and aetiological aspects
Mann, D. M. A. (1994) · Reviews in Clinical Gerontology · doi:10.1017/s0959259800002252 · Cited by 10
Exercise to Counteract Alzheimer’s Disease: What Do Fluid Biomarkers Say?
Bonanni, R., Cariati, I., Cifelli, P., Frank, C., Annino, G., Tancredi, V., & D’Arcangelo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136951 · Cited by 8
“The finding of A β in CSF dates to 1992, when Seubert and colleagues demonstrated that the peptide responsible for AD was produced and released both in vivo and in vitro, laying the foundation for the development of diagnostic tests based on the presence of amyloid in CSF [37].”
BackgroundGui, S., Zeng, F., Wu, Z., Nonaka, S., Sano, T., Ni, J., Nakanishi, H., Moriyama, M., & Kanematsu, T. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251326879 · Cited by 8
Krüger, L., Biskup, K., Schipke, C. G., Kochnowsky, B., Schneider, L., Peters, O., & Blanchard, V. (2024) · Biomolecules · doi:10.3390/biom14050512 · Cited by 9
“The A β -peptides, which are secreted during cellular metabolism as normal components of the CSF [38,39], are downregulated by 50% in AD patients [40].”
BackgroundSkaat, H. (2013) · Journal of Biotechnology & Biomaterials · doi:10.4172/2155-952x.1000156 · Cited by 8
“Aβ is continuously secreted by normal cells in culture, and is a component of plasma and cerebrospinal fluid of healthy individuals in the soluble form [8,9].”
BackgroundImpairment of visual cortical plasticity by amyloid-beta species
William, C. M., Stern, M., Pei, X., Saqran, L., Ramani, M. D., Frosch, M. P., & Hyman, B. T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105344 · Cited by 10
Gaudreault, R., Hervé, V., van de Ven, T. G. M., Mousseau, N., & Ramassamy, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201549 · Cited by 10
“In human blood, circulating blood cells 28 are exposed to nanomolar levels of soluble Aβ40/42 [161].”
Biomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
Marcucci, V., & Kleiman, J. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00016 · Cited by 9
Toniolo, S., Lorenzo, F. D., Bernardini, S., Mercuri, N. B., & Sancesario, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512151 · Cited by 8
“5 nM), Aβ deposits are largely found in the interstitial compartments within the brain [19].”
BackgroundUpdate on amyloid‐βhomeostasis markers for sporadic Alzheimer's disease
Zetterberg, H. (2009) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802651841 · Cited by 8
Powell, L. R., Dukes, K. D., & Lammi, R. K. (2011) · Biophysical Chemistry · doi:10.1016/j.bpc.2011.08.006 · Cited by 10
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 10
Ginotra, Y. P., Ramteke, S., Walke, G. R., Rapole, S., & Kulkarni, P. P. (2015) · Free Radical Research · doi:10.3109/10715762.2015.1133907 · Cited by 9
Angiotensin converting enzyme and Alzheimer’s disease
Kugaevskaya, E. V. (2012) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075081201009x · Cited by 9
Angiotensin converting enzyme and Alzheimer's disease
Kugaevskaya, E. V. (2013) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20135901005 · Cited by 10
Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic
Stiffel, M., Bergeron, D., Amari, K. M., Poulin, É., Roberge, X., Meilleur‐Durand, S., Sellami, L., Molin, P., Nadeau, Y., Fortin, M., et al. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.67 · Cited by 10
“We collected a total of 5-20 ml of CSF divided into three to four sterile polypropylene tubes of approximately 10ml of CSF each: (1) cell count; (2) glucose, proteins; (3) AD biomarkers; and (4) further infectious and/or autoimmune investigation in select cases.”
MethodChaperoning Alzheimer's amyloids
Frangione, B., Wısnıewskı, T., & Ghiso, J. A. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90182-1 · Cited by 8
Barritt, J. D., Younan, N. D., & Viles, J. H. (2017) · Angewandte Chemie · doi:10.1002/ange.201704618 · Cited by 10
Is Understanding the Biological Function of APP Important in Understanding Alzheimer's Disease?
Saitoh, T., & Mook‐Jung, I. (1999) · Journal of Alzheimer s Disease · doi:10.3233/jad-1999-14-509 · Cited by 9
Biochemical Diagnostic Markers to Detect Early Alzheimer’s Disease
Lannfelt, L. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00012-8 · Cited by 8
Active clearance of human amyloid β 1–42 peptide aggregates from the rat ventricular system
Nakagawa, Y., Yuzuriha, T., & Iwaki, T. (2004) · Neuropathology · doi:10.1111/j.1440-1789.2004.00549.x · Cited by 12
“Our model thus allows a much higher concentration of sAb to be loaded than the physiological concentration of CSF into the rat ventricular system.(5,9) We filled a transparent vinylchloride chateter with 100 mg of sAb 1–42.”
MethodTokuda, T., Tanaka, K., Kametani, F., Ikeda, S., & Yanagisawa, N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11307-i · Cited by 10
Mattila, K. M., & Frey, H. (1994) · Electrophoresis · doi:10.1002/elps.1150150199 · Cited by 8
Artifactual strain-specific signs of incipient brain amyloidosis in APP transgenic mice
Ali, S. M., Siedlak, S. L., Gonzalez‐DeWhitt, P. A., Altman, R. A., Glendening, J. M., Lowery, D. E., Savage, M. J., Polities, H. G., Perry, G. L., & Greenberg, B. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02065-9 · Cited by 8
Catastrophe, Chaos and Alzheimer's Disease
Rossor, M. N. (1995) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)00542-2 · Cited by 9
Biomarkers of Alzheimer's Disease: A Review
Mohapatra, D., Jena, S. R., Prusty, S. K., & Sahu, P. K. (2020) · Systematic Reviews in Pharmacy · doi:10.31838/srp.2020.6.24 · Cited by 7
“This biomarker can be measured by Enzyme linked immunosorbent assay (ELISA) and mass spectrometry method [25].”
MethodIdentification of Molecular Correlations of GSDMD with Pyroptosis in Alzheimer's Disease
Song, T., Chen, Y., Li, C., Yao, Y., Ma, S., Yazhen, S., & Cheng, J. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073285497240226061936 · Cited by 9
Cao, Y., Zhu, X., Li, J., & Chen, K. (2009) · Journal of Molecular Structure THEOCHEM · doi:10.1016/j.theochem.2009.04.014 · Cited by 7
Kurt, A. H., Yüksel, K. Z., Üremiş, N., Üremiş, M. M., Altun, İ., Boşnak, M., Kılıçaslan, D., & Alli, B. (2019) · Neurochemical Journal · doi:10.1134/s1819712419010148 · Cited by 7
THE NEUROPATHOLOGY OF ALZHEIMER'S DISEASE
Wisniewski, H. M., & Węgiel, J. (1995) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00275-8 · Cited by 32
Lowenson, J. D., Roher, A. E., & Clarke, S. G. (1994) · Trends in Cardiovascular Medicine · doi:10.1016/1050-1738(94)90019-1 · Cited by 7
Lower levels of cerebrospinal fluid amyloid ß (Aß) in non-demented Indian controls
Subramanian, S., Sandhyarani, B., Shree, A., Murthy, K. K., Kalyani, K., Kumar, S., Pradeep, P., Noone, M. J., & Taly, A. B. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.018 · Cited by 8
Pentreath, V. W., & Mead, C. (2004) · Nonlinearity in Biology Toxicology Medicine · doi:10.1080/15401420490426990 · Cited by 9
“Approximately half of the βAP is normally buried in the neuronal cell membranes with the other section (N-terminus) projecting extracellularly.”
BackgroundAssociation of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects
Millard, S. P., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., Yu, C., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.027 · Cited by 8
Ng, O. T.-W., Wong, Y., Chan, H., Cheng, J., Xiao, Q., Chan, W. H., Yung, K. K. L., & Li, H. (2013) · Biomaterials Science · doi:10.1039/c3bm60029g · Cited by 7
Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease
Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 13
Effect of Cu2+ and Zn2+ ions on human serum albumin interaction with plasma unsaturated fatty acids
Леонидовна, Н. Е., Permyakov, E. A., Uversky, V. N., Permyakov, S. E., & Андреевна, Л. Е. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.085 · Cited by 8
Effects of Ions and Small Compounds on the Structure of Aβ42 Monomers
Mahmoudinobar, F., Nilsson, B. L., & Dias, C. L. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c09617 · Cited by 7
Feedback Regulation of SREBP and Aromatase in A β(25-35)-Supplemented Human Neuroblastoma Cells
Kelicen, P., & Nordberg, A. K. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9060-x · Cited by 7
“Furthermore, β- and γ-secretase processing of APP (at the N- and C-termini of the Aβ sequence) also occurs under physiological conditions (Haass et al., 1992b; Seubert et al., 1992).”
BackgroundIdentification of a novel serine protease-like molecule in human brain
Meckelein, B., Marshall, D. C. L., Conn, K. J., Pietropaolo, M., Nostrand, W. V., & Abraham, C. R. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00366-5 · Cited by 9
Subpial peptide deposits are closely associated with amyloid angiopathy in the elderly
Itoh, Y., Yamada, M., Hayakawa, M., Otomo, E., & Miyatake, T. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90693-f · Cited by 7
Smith, C., Stanyer, L., Betteridge, D. J., & Cooper, M. B. (2007) · Clinical Science · doi:10.1042/cs20070082 · Cited by 7
Greenberg, B., & Murphy, M. F. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90184-8 · Cited by 7
The role of β-amyloid peptide in alzheimer's disease
LeBlanc, A. C. (1994) · Metabolic Brain Disease · doi:10.1007/bf01996071 · Cited by 7
Etiological Clues from Gene Defects Causing Early Onset Familial Alzheimer’s Disease
Wasco, W., & Tanzi, R. E. (1997) · Humana Press eBooks · doi:10.1007/978-1-59259-471-9_1 · Cited by 7
Chapter 6. Perspectives on Amyloid and Alzheimer's Disease: A Critical Review
Krafft, G. A. (1993) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60876-3 · Cited by 8
Blitzer, R. D., Wong, T., Giovannini, M. G., Pangalos, M. N., Robakis, N. K. R. K., & Landau, E. M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00340-x · Cited by 7
Development in the research of molecular mechanism of Alzheimer’s disease
Gu, M., Wang, X., Mu, Y., & Fan, M. (1999) · Chinese Science Bulletin · doi:10.1007/bf02885840 · Cited by 7
Kaplan, B. (1998) · Analytica Chimica Acta · doi:10.1016/s0003-2670(98)00336-5 · Cited by 8
Essalmani, R., Guillaume, J. M., Mercken, L., & Octave, J. N. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00561-3 · Cited by 7
Tau proteins and their significance in the pathobiology of Alzheimer's disease
Lee, V. M. ‐., & Trojanowski, J. Q. (1995) · Elsevier eBooks · doi:10.1016/b978-012286965-5/50005-4 · Cited by 8
CELLULAR AND MOLECULAR BASIS OF β-AMYLOID PRECURSOR PROTEIN METABOLISM
Greenfield, J. P., Gross, R. S., Gouras, G. K., & Xu, H. (2000) · Cited by 9
Strategic Thoughts on the Alzheimer’s Disease Amyloid Protein Precursor: The Way Forward
Masters, C. L., & Beyreuther, K. T. (1994) · Springer eBooks · doi:10.1007/978-3-662-01135-5_1 · Cited by 7
Pinheiro, N. R., Carneiro, C. F. D., Cancelliero, G. S., Nogueira, G. O., de Almeida, G. M., Fernandes, N., Wasilewska‐Sampaio, A. P., Martins, S. M., Filho, A. F. D. S., Amaral, O. B., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70523 · Cited by 9
“Such differences may explain the wide range of Aβ concentrations used in studies using SH-SY5Y as a model—including some that are much higher than those found in vivo (Hu et al. 2009; Seubert et al. 1992).”
Molecular Insight into the Effect of HIV-TAT Protein on Amyloid-β Peptides
Jana, A. K., Keskin, R., & Yaşar, F. (2024) · ACS Omega · doi:10.1021/acsomega.4c02643 · Cited by 6
A Sensitive Aβ Oligomerization Assay for Identification of Small Molecule Inhibitors
Gonzales, A. M., & Orlando, R. A. (2009) · The Open Biotechnology Journal · doi:10.2174/1874070700903010108 · Cited by 7
“Questions have arisen asking if these in vitro reactions are truly reflective of oligomerization in vivo since it is unlikely that localized brain levels of peptide would ever reach these concentrations [22-25].”
Kozin, S. A., & Makarov, A. А. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2015115115-9 · Cited by 6
“Он содержится в биологических жидкостях (кровь, цереброспинальная жидкость) в субнаномолярных концентрациях, которые одинаковы как для больных, так и здоровых людей [9, 10].”
Metadata
- Authors
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., & Schenk, D.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6393
- Pages
- 325-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2086278983
- Cited by
- 1,731
- References
- 28
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 32 · 2023: 19 · 2022: 22 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 35 · 2017: 39 · 2016: 31 · 2015: 48 · 2014: 46 · 2013: 39 · 2012: 50
- FWCI
- 72.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, cerebrospinal fluid, plasma, conditioned medium, sandwich ELISA, affinity chromatography, epitope-specific antibodies, amyloid deposition, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Antibodies, Monoclonal, Brain, Cells, Cultured, Cross Reactions, Enzyme-Linked Immunosorbent Assay, Humans, Molecular Sequence Data, Peptide Fragments, Radioimmunoassay, Solubility, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.